Kromě řady menších studií s nadějnými výsledky bylo provedeno několik velkých klinických studií ověřujících účinek probiotického kmene
Streptococcus salivarius K12.
Zde jsou uvedeny:
Di Pierro et al |
2013 |
Italy |
Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opin Biol Ther. 2013 Mar;13(3):339-43. |
Di Pierro et al |
2012 |
Italy |
Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012;5:991-7 |
Ishijima et al |
2012 |
Japan and New Zealand |
Effect of Streptococcus salivarius K12 on the in vitro growth of Candida albicans and its protective effect in an oral candidiasis model. Appl Environ Microbiol. 2012 Apr;78(7):2190-9. |
Guglielmetti et al |
2010 |
Italy |
Oral bacteria as potential probiotics for the pharyngeal mucosa. Appl Environ Microbiol. 2010 Jun;76(12):3948-58. |
Horz et al |
2007 |
Germany |
Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. Oral Microbiol Immunol. 2007 Apr;22 (2):126-30. |
Tagg et al |
2006 |
New Zealand |
Oral streptococcal BLIS: Heterogeneity of the effector molecules and potential role in the prevention of streptococcal infections. International Congress Series, 2006, Vol 128: 347-350 |
Wescombe et al |
2006 |
New Zealand |
Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. Appl. Environ. Microbiol. 2006 Feb 72(2):1459-1466. |
Tagg et al |
2004 |
New Zealand |
Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius. Indian J Med Res. 2004 May;119 Suppl:13-6. |
Dierksen et al |
2000 |
New Zealand |
The influence of indigenous bacteriocin-producing Streptococcus salivarius on the acquisition of Streptococcus pyogenes by primary school children in Dunedin, New Zealand. In: Streptococci and streptococcal diseases entering the new millennium. 2000 p81-85. |
DENTAL HEALTH |
|||
Burton et al |
2013 |
New Zealand |
Influence of the probiotic Streptococcus salivarius strain M18 on indices of dental health in children: a randomized double-blind, placebo-controlled trial. J. Med. Microbiol. 2013 62:DOI 10.1099/jmm.0.056663-0 |
James & Tagg |
1991 |
New Zealand |
The prevention of dental caries by BLIS-mediated inhibition of mutans streptococci. N Z Dent J. 1991 Jul;87(389):80-3. |
UPPER RESPIRATORY TRACT INFECTIONS |
|||
Fiedler et al |
2013 |
Germany |
Protective mechanisms of respiratory tract Streptococci against Streptococcus pyogenes biofilm formation and epithelial cell infection. Appl Environ Microbiol. 2013 Feb;79(4):1265-76. |
Di Pierro et al |
2012 |
Italy |
Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012;5:991-7 |
Santagati et al |
2012 |
Italy |
Bacteriocin-producing oral streptococci and inhibition of respiratory pathogens. FEMS Immunol Med Microbiol 2012 65:23-31 |
Power et al |
2008 |
New Zealand |
Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis. 2008 Jun 17. |
HALITOSIS |
|||
Masdea et al |
2012 |
Switzerland |
Antimicrobial activity of Streptococcus salivarius K12 on bacteria involved in oral malodour. |
Burton et al |
2006 |
New Zealand |
A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters, J Appl Microbiol. 2006 Apr; 100(4):754-64. |
Kazor et al |
2003 |
USA |
Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. J. Clin. Microbiol. 2003 Feb;41(2):558-563 |
SAFETY |
|||
Barretto et al |
2012 |
Switzerland |
Genome sequence of the lantibiotic bacteriocin producer Streptococcus salivarius strain K12. J Bacteriol. 2012 Nov;194(21):5959-60. |
Burton et al |
2011 |
New Zealand and USA |
Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study. Food Chem Toxicol. 2011 Sep;49(9):2356-64. |
Heng et al |
2011 |
New Zealand |
Genome sequence of the bacteriocin-producing oral probiotic Streptococcus salivarius strain M18. J. Bact. 2011 Nov 193:6402-6403 |
Burton et al |
2010 |
New Zealand |
Extended safety data for the oral cavity probiotic Streptococcus salivarius K12. Probiotics and Antimicro. Prot. 2010 2:135-144. |
Burton et al |
2006 |
New Zealand |
Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. Appl Environ Microbiol. 2006 Apr;72(4):3050-3. |
IMMUNITY |
|||
Groeger et al |
2011 |
Germany |
B7-H1 and B7-DC receptors of oral squamous carcinoma cells are upregulated by Porphyromonas gingivalis. Immunobiology. 2011 Dec;216(12):1302-10. |
Cosseau et al |
2008 |
Canada and United Kingdom |
The commensal Streptococcus salivarius K12 down-regulates the innate immune responses of human epithelial cells and promotes hostmicrobe homeostasis. Infection and Immunity, Sept. 2008, p. 4163–4175 |
OTITIS MEDIA |
|||
Di Pierro et al |
2012 |
Italy |
Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012;5:991-7. |
Tagg et al |
2003 |
New Zealand |
Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media? J Med Microbiol. 2003 Sep;52(Pt 9):829-33. |
Wescombe et al |
2006 |
New Zealand & Canada |
Megaplasmids encode differing combinations of lantibiotics in Streptococcus salivarius, Antonie Van Leeuwenhoek. 2006 Oct;90 (3):269-80 |
Hyink et al. |
2007 |
New Zealand |
Salivaricin A2 and the novel antibiotic salivaricin B, are encoded by adjacent loci on a 190 kb transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol 73(4): 1107-13. |
Wescombe et al |
2006 |
New Zealand |
Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. Appl Environ Microbiol. 2006 Feb;72(2):1459-66. |
REVIEWS |
|||
Wescombe et al |
2012 |
New Zealand |
Developing oral probiotics from Streptococcus salivarius. Future Microbiol. 2012 7(12):1355-1371. |
Hale et al |
2012 |
New Zealand |
BLIS-producing probiotics targeting the oral cavity. Microbiology Australia. 2012 Sept 33(3):103-105. |
Burton et al |
2011 |
New Zealand and Canada |
Beneficial microbes for the oral cavity: time to harness the oral streptococci? Beneficial microbes. 2011 June 2(2):93-101 |
Wescombe et al |
2010 |
New Zealand |
Something old and something new: An update on the amazing repertoire of bacteriocins produced by Streptococcus salivarius. Probiotics & Antimicro. Prot. 2010 2:37-45 |
Tagg |
2009 |
New Zealand |
Streptococcal bacteriocin-like inhibitory substances: some personal insights into the bacteriocin-like activities produced by streptococci good and bad. Probiotics and Antimicro. Prot. 2009 1:60-66. |
Wescombe et al |
2009 |
New Zealand |
Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics. Future Microbial. 2009 4(7):819-35 |
Tagg et al |
2008 |
New Zealand |
Streptococci as effector organisms for probiotic and replacement therapy. In: Therapeutic Microbiology: Probiotic and Related Strategies. J. Versalovic and M. Wilson, American Society for Microbiology. p61-81. |
Tagg |
2007 |
New Zealand |
Application of bacterial pathogens in replacement therapy. In: Patho-Biotechnology. R. Sleator and C. Hill Landes Bioscience. |
Heng et al |
2007 |
New Zealand |
The diversity of bacteriocins in gram-positive bacteria. In: Ecology and Evolution. M. Riley and M. Chavan. p45-92. |
Tagg et al |
2003 |
New Zealand |
Bacterial replacement therapy: adapting ‚germ warfare‘ to infection prevention, Trends Biotechnol. 2003 May;21 (5):217-23. |